Previous 10 | Next 10 |
Verve is a new IPO formed by world experts in cardiology and genetics. It has preclinical assets targeting cardiovascular diseases. Despite a high valuation, VERV looks interesting. For further details see: Verve Therapeutics: Pioneering Cardiovascular Medicine Using The...
A recent study has flagged a new safety signal that could potentially hurt the drug developers focused on CRISPR–Cas9 gene editing. The condition known as chromothripsis has the potential to cause cancer eventually, according to the study conducted by Mitchell Weiss of St. Jude Childre...
New Preclinical Base Editing Durability Data and Proprietary GalNAc-targeted Lipid Nanoparticle Delivery Technology Data to be Presented at TIDES in September 2021 VERVE-101 IND-Enabling Studies Ongoing to Support Planned IND Submission in 2022 Successful $306.7 Million ...
Andy/iStock via Getty Images An expert panel from the World Health Organization ((WHO)) has called for a generous distribution of gene editing technologies to enable the poorer countries to benefit from the medical field that recently gained worldwide attention. "WHO should work with others t...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead It's that time again, as second-quarter earnings season kicks off in earnest with the usual early reports from banks - J...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
rommma/iStock via Getty Images The companies focused on gene editing have edged lower today after a sharp rally last week driven by positive early-stage data from Intellia Therapeutics ([[NTLA]] -8.7%) for its gene-editing candidate NTLA-2001 in rare disease, transthyretin amyloidosis ("ATTR"...
Matteo Colombo/DigitalVision via Getty Images S&P 500 Health Care Sector Index rose ~2.0% over the week to outpace the ~1.7% gain in the S&P 500 as gene editing companies rallied after Intellia (NTLA) and Regeneron (REGN) showed promise in the CRISPR technology with fir...
Brian Ach/Getty Images Entertainment Intellia Therapeutics ([[NTLA]] +7.7%) has gained more than 80.0% since the company joined Gilead Sciences ([[GILD]] +1.2%) over the weekend to unveil the first first-ever clinical data to support the safety and efficacy of in-vivo CRISPR genome editi...
Gainers: Ocuphire Pharma (OCUP) +26%, Predictive Oncology (POAI) +21%, Verve Therapeutics (VERV) +21%, HUTCHMED (China) (HCM) +21%, Intellia Therapeutics (NTLA) +19%.Losers: Altimmune (ALT) -36%, electroCore (ECOR) -28%,...
News, Short Squeeze, Breakout and More Instantly...
Verve Therapeutics Inc. Company Name:
VERV Stock Symbol:
NASDAQ Market:
Verve Therapeutics Inc. Website:
2024-07-08 07:42:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced the appointment of Nia Tatsis, Ph.D., and Jodie Morrison to its boar...
2024-06-15 11:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...